Back to mobile site

Gilead Sciences (GILD) Reiterated at Overweight by Cantor Fitzgerald on Yeztugo TRx Gains

April 6, 2026 7:39 AM EDT Send to a Friend
Cantor Fitzgerald analyst Carter Gould reiterated an Overweight rating and $155.00 price target on Gilead Sciences (NASDAQ: GILD).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login